Kangtai Biological received the summary report of the Phase I/III clinical trial of adsorbed tetanus vaccine
March 5, 2025
Source: drugdu
30
On the evening of March 3, Kangtai Biological (300601) issued an announcement stating that the company's wholly-owned subsidiary Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as "Minhai Biotechnology") recently received the summary report of the Phase I/III clinical trial of adsorbed tetanus vaccine, and the clinical research phase of the adsorbed tetanus vaccine developed by Minhai Biotechnology was successfully completed.
The results of the study showed that the adsorbed tetanus vaccine developed by Minhai Biotechnology has good safety and immunogenicity for adult immunization. Kangtai Biological said that the acquisition of the summary report of the Phase I/III clinical trial of the adsorbed tetanus vaccine shows that the adsorbed tetanus vaccine has the necessary conditions for application for production, which is of great significance to the development of the company.
https://finance.eastmoney.com/a/202503033334982519.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Tonghua Dongbao’s net profit is expected to decrease by 99% in 2024. Can the transformation and survival break through? March 5, 2025
- New indication for ustekinumab approved March 5, 2025
- Why did the first mesenchymal stem cell drug in the United States set a “sky high price”! March 5, 2025
- One innovative medical device enters special review process March 5, 2025
- Promote the high-quality development of Chengdu-Chongqing biopharmaceutical industry and create an innovative growth pole in the west March 5, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
